Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04349358 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

FCH vs FDG PET/CT in Detection of Lesions in Patients With Multiple Myeloma (MIM)

Study acronym: MIM
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv4
  2. Primary completion date: Feb 15, 2022 to Dec 15, 2022 Completion date: Feb 15, 2030 to Dec 15, 2030 · Eligibility criteria expanded, about 17 words · Site details revised at 2 of 3 sitesv3 Show 3 more changesShow less
    • Completion date: Feb 15, 2030 to Dec 15, 2030
    • Eligibility criteria expanded, about 17 words
    • Site details revised at 2 of 3 sites

    See this version in full on ClinicalTrials.gov ↗

  3. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jun 2020 to Dec 15, 2020 · Primary completion date: Aug 2021 to Feb 15, 2022 · Completion date: Aug 2029 to Feb 15, 2030 · 1 morev2 Show 4 more changesShow less
    • Start date changed from estimate of Jun 2020 to Dec 15, 2020
    • Primary completion date: Aug 2021 to Feb 15, 2022
    • Completion date: Aug 2029 to Feb 15, 2030
    • Site details revised at 3 of 3 sites
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Hybrid positron emission tomography/computed tomography (PET/CT) has now become available to detect tumors in patients with multiple myeloma. The radioactive glucose 18F-fluorodeoxyglucose (FDG) is the most widely used tracer but findings suggest that PET/CT reveal more lesions when using FCH. In this study, FDG is compared with a more recent metabolic tracer, 18F-fluorocholine (FCH), for the detection of multiple myeloma lesions at time of initial extension assessment. The principal objective of this sudy is to compare the number of suspected hypermetabolic foci of myeloma detected by 18F-fluorocholine PET and by 18F-fluorodeoxyglucose PET during the initial extension assessment.
Trial Details
NCT Number NCT04349358
Lead Sponsor Centre Georges Francois Leclerc
Conditions Multiple Myeloma
Enrollment 38 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov